Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry

被引:121
作者
Fieffe, Sandrine [1 ]
Morange, Isabelle [2 ,3 ]
Petrossians, Patrick [4 ]
Chanson, Philippe [5 ]
Rohmer, Vincent [6 ]
Cortet, Christine [7 ]
Borson-Chazot, Francoise [8 ]
Brue, Thierry [2 ,3 ]
Delemer, Brigitte [1 ]
机构
[1] CHU Reims, Hop Robert Debre, Serv Endocrinol, F-51092 Reims, France
[2] Hop La Timone, Serv Endocrinol Diabet & Malad Metab, F-13385 Marseille, France
[3] Hop La Timone, Ctr Reference Malad Rares Origine Hypophysaires, F-13385 Marseille, France
[4] CHU Liege, Serv Endocrinol, B-4020 Liege, Belgium
[5] CHU Bicetre, Serv Endocrinol, F-94275 Le Kremlin Bicetre, France
[6] CHU Angers, Serv Endocrinol, F-49033 Angers, France
[7] Clin Marc Linquette, Serv Endocrinol, F-59037 Lille, France
[8] Hop Antiquaille, Serv Endocrinol, F-69005 Lyon, France
关键词
GLUCOSE-METABOLISM; SOMATOSTATIN ANALOGS; GROWTH-HORMONE; EPIDEMIOLOGY; TOLERANCE; MORTALITY; SURGERY; MODULATION; MORBIDITY; DISEASE;
D O I
10.1530/EJE-10-1050
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The French Acromegaly Registry records data of acromegalic patients' since 1992 in French, Belgian (Liege), and Swiss (Lausanne) centers. We studied the prevalence of diabetes in this population looking for risk factors. Patients from one of the centers (Reims) were then analyzed more thoroughly. Methods: This study has been conducted on all the patients recorded from 1999 until 2004 (519 patients). Evolution of cohorts' was reassessed in 2009. Of the different variables recorded in the registry: age, sex, body mass index (BMI), duration of acromegaly, GH, IGF1 and prolactin levels, pituitary tumor size, hormonal deficiencies, presence, duration and treatment of diabetes, hypertension, and rheumatological disease were analyzed. Results: The prevalence of diabetes in the registry was 22.3%. Diabetic patients were older and had a higher BMI. Compared with the data of the French Social Security, acromegalic patients showed a more precocious apparition of diabetes and prevalence was higher in each age group. Compared with non-diabetic acromegalic subjects, diabetic patients had a more prolonged evolution of acromegaly before diagnosis. The levels of GH and IGF1 were not significantly different between the two groups. Only hypertension was significantly more frequent in diabetic patients. Conclusions: In our population, the prevalence of diabetes was estimated to be 22.3%. The GH and IGF1 levels did not appear as predictive factors for the presence of diabetes. On the contrary, age, BMI, and hypertension were significant risk factors as in the general population of type 2 diabetics.
引用
收藏
页码:877 / 884
页数:8
相关论文
共 34 条
  • [21] Impaired glucose metabolism in Japanese patients with acromegaly is restored after successful pituitary surgery if pancreatic β-cell function is preserved
    Kinoshita, Yuka
    Fujii, Hiroko
    Takeshita, Akira
    Taguchi, Manabu
    Miyakawa, Megumi
    Oyama, Kenich
    Yamada, Shozo
    Takeuchi, Yasuhiro
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2011, 164 (04) : 467 - 473
  • [22] Prevalence and treatment of diabetes in France: Trends between 2000 and 2005
    Kusnik-Joinville, O.
    Weill, A.
    Salanavea, B.
    Ricordeau, P.
    Allemand, H.
    [J]. DIABETES & METABOLISM, 2008, 34 (03) : 266 - 272
  • [23] Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy
    Mazziotti, Gherardo
    Porcelli, Teresa
    Bogazzi, Fausto
    Bugari, Giovanna
    Cannavo, Salvatore
    Colao, Annamaria
    Cozzi, Renato
    De Marinis, Laura
    degli Uberti, Ettore
    Grottoli, Silvia
    Minuto, Francesco
    Montini, Marcella
    Spinello, Maurizio
    Giustina, Andrea
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2011, 164 (03) : 341 - 347
  • [24] Medical progress: Acromegaly
    Melmed, Shlomo
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (24) : 2558 - 2573
  • [25] Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espahol de Acromegalia, REA)
    Mestrón, A
    Webb, SM
    Astorga, R
    Benito, P
    Catalá, M
    Gaztambide, S
    Gómez, JM
    Halperín, I
    Lucas-Morante, T
    Moreno, B
    Obiols, G
    de Pablos, P
    Páramo, C
    Picó, A
    Torres, E
    Varela, C
    Vázquez, JA
    Zamora, J
    Albareda, M
    Gilabert, M
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2004, 151 (04) : 439 - 446
  • [26] BASAL-STIMULATED AND INSULIN-STIMULATED SUBSTRATE METABOLISM IN PATIENTS WITH ACTIVE ACROMEGALY BEFORE AND AFTER ADENOMECTOMY
    MOLLER, N
    SCHMITZ, O
    JORGENSEN, JOL
    ASTRUP, J
    BAK, JF
    CHRISTENSEN, SE
    ALBERTI, KGMM
    WEEKE, J
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 74 (05) : 1012 - 1019
  • [27] Effects of Growth Hormone on Glucose, Lipid, and Protein Metabolism in Human Subjects
    Moller, Niels
    Jorgensen, Jens Otto Lunde
    [J]. ENDOCRINE REVIEWS, 2009, 30 (02) : 152 - 177
  • [28] ACROMEGALY
    NABARRO, JDN
    [J]. CLINICAL ENDOCRINOLOGY, 1987, 26 (04) : 481 - 512
  • [29] Neggers SJCMM, 2011, ENDOCR DEV, V20, P181, DOI 10.1159/000321243
  • [30] Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly
    Puder, JJ
    Nilavar, S
    Post, KD
    Freda, PU
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (04) : 1972 - 1978